The future of personalized tumor models is promising, with ongoing research and technological advancements aimed at overcoming current limitations. Innovations in genomics, CRISPR technology, and artificial intelligence are expected to enhance the accuracy and utility of these models. Collaboration between academic institutions, pharmaceutical companies, and healthcare providers will be crucial in translating these advancements into clinical practice.
